Amicus Therapeutics’ (FOLD) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a research note published on Wednesday,Benzinga reports. The brokerage currently has a $21.00 target price on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on FOLD. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Bank of America upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. Guggenheim increased their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Monday, January 13th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.88.

Amicus Therapeutics Price Performance

Shares of FOLD stock opened at $9.41 on Wednesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. The company has a market capitalization of $2.81 billion, a PE ratio of -27.68, a price-to-earnings-growth ratio of 1.25 and a beta of 0.62. The firm’s 50-day moving average is $9.70 and its two-hundred day moving average is $10.52. Amicus Therapeutics has a 12 month low of $8.78 and a 12 month high of $14.03.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,901 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $11,083,175. This trade represents a 0.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders have sold 22,901 shares of company stock worth $259,863 over the last three months. Company insiders own 2.20% of the company’s stock.

Institutional Trading of Amicus Therapeutics

Several hedge funds have recently modified their holdings of FOLD. Xponance Inc. grew its stake in Amicus Therapeutics by 5.3% during the 2nd quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 936 shares in the last quarter. Hazlett Burt & Watson Inc. grew its position in shares of Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,569 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Amicus Therapeutics by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 1,884 shares in the last quarter. OLD Second National Bank of Aurora purchased a new stake in shares of Amicus Therapeutics during the third quarter worth approximately $26,000. Finally, AlphaCentric Advisors LLC raised its holdings in Amicus Therapeutics by 1.2% in the third quarter. AlphaCentric Advisors LLC now owns 205,000 shares of the biopharmaceutical company’s stock valued at $2,189,000 after acquiring an additional 2,500 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.